Clinical Trial Results:
The pain relieving effect of nitrous oxide during bone marrow aspiration and biopsy - a placebo-controlled and randomized trial
Summary
|
|
EudraCT number |
2012-004285-18 |
Trial protocol |
FI |
Global end of trial date |
20 Mar 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
13 Dec 2021
|
First version publication date |
13 Dec 2021
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
00002
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Helsinki and Uusimaa Hospital District
|
||
Sponsor organisation address |
Haartmaninkatu 4, Helsinki, Finland, 00029
|
||
Public contact |
Per Rosenberg, Helsingin yliopisto, +358 9471 72 510,
|
||
Scientific contact |
Per Rosenberg, Helsingin yliopisto, +358 9471 72 510,
|
||
Sponsor organisation name |
Helsinki University Hospital
|
||
Sponsor organisation address |
Haartmaninkatu 4, Helsinki, Finland, 00029
|
||
Public contact |
Anna-Maria Kuivalainen, Helsinki and Uusimaa Hospital District, Helsinki University Hospital, anna-maria.kuivalainen@helsinki.fi
|
||
Scientific contact |
Anna-Maria Kuivalainen, Helsinki and Uusimaa Hospital District, Helsinki University Hospital, anna-maria.kuivalainen@helsinki.fi
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
30 May 2014
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
20 Mar 2014
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
20 Mar 2014
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The aim of this study was to find out if inhalation of a 50% mixture of N2O and oxygen is effective in relieving procedural pain in adults during bone maarow aspiration and/or biopsy compared to 50% oxygen.
|
||
Protection of trial subjects |
The ethics committee of Helsinki and Uusimaa Hospital District approved the study protocol before the start of the trial (Diary number 323/13/03/01/2012). The ethical principles of Helsinki declaration were followed during every step of the clinical trial.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
23 May 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Finland: 70
|
||
Worldwide total number of subjects |
70
|
||
EEA total number of subjects |
70
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
46
|
||
From 65 to 84 years |
24
|
||
85 years and over |
0
|
|
||||||||||
Recruitment
|
||||||||||
Recruitment details |
Adult outpatients from the Division of Haematology undergoing bone marrow aspiration and/or biopsy were considered for inclusion. Patients were interviewed and screened for predetermined exclusion criteria before enrollment. | |||||||||
Pre-assignment
|
||||||||||
Screening details |
144 patients were considered for randomization. 74 patients were excluded and 70 patients were randomized. | |||||||||
Period 1
|
||||||||||
Period 1 title |
Overall trial (overall period)
|
|||||||||
Is this the baseline period? |
Yes | |||||||||
Allocation method |
Randomised - controlled
|
|||||||||
Blinding used |
Single blind | |||||||||
Roles blinded |
Subject | |||||||||
Arms
|
||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||
Arm title
|
Nitrous oxide arm | |||||||||
Arm description |
Patients receiving 50% mixture of nitrous oxide and oxygen | |||||||||
Arm type |
Experimental | |||||||||
Investigational medicinal product name |
50% mixture of nitrous oxide and oxygen
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Medicinal gas, compressed
|
|||||||||
Routes of administration |
Inhalation use
|
|||||||||
Dosage and administration details |
Patients started inhalation when the procedure was about to begin. After 2-3 minutes of inhalation, procedure was started. Patients inhaled countinuously throughout the procedure. After the procedure was completed, inhalation was stopped.
|
|||||||||
Arm title
|
Placebo arm | |||||||||
Arm description |
Patients receiving 50% oxygen arm | |||||||||
Arm type |
Placebo | |||||||||
Investigational medicinal product name |
50% oxygen
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Medicinal gas, compressed
|
|||||||||
Routes of administration |
Inhalation use
|
|||||||||
Dosage and administration details |
Patients started inhalation when the procedure was about to begin. After 2-3 minutes of inhalation, procedure was started. Patients inhaled continuously throughout the procedure. After the procedure, patients stopped inhalation.
|
|||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Nitrous oxide arm
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients receiving 50% mixture of nitrous oxide and oxygen | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo arm
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients receiving 50% oxygen arm | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Nitrous oxide arm
|
||
Reporting group description |
Patients receiving 50% mixture of nitrous oxide and oxygen | ||
Reporting group title |
Placebo arm
|
||
Reporting group description |
Patients receiving 50% oxygen arm |
|
|||||||||||||||||||||||||
End point title |
Pain during procedure | ||||||||||||||||||||||||
End point description |
|||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||
End point timeframe |
Pain during bone marrow aspiration and/or biopsy procedure
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Statistical analysis title |
Statistical analysis | ||||||||||||||||||||||||
Statistical analysis description |
The normality of the variables was assessed with the Shapiro–Wilk test. Ordinal regression analysis stratified by phase of the procedure was used to analyse the differences in pain felt during BMAB in both groups.
|
||||||||||||||||||||||||
Comparison groups |
Nitrous oxide arm v Placebo arm
|
||||||||||||||||||||||||
Number of subjects included in analysis |
70
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||||||
Method |
Regression, Logistic | ||||||||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
- | ||||||||||||||||||||||||
upper limit |
- |
|
|||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From the start of study treatment until end of follow-up interview on the following day.
|
||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
1
|
||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Treatment arm
|
||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients receiving 50% mixture of nitrous oxide and oxygen | ||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo arm
|
||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients receiving 50% oxygen | ||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/29911602 |